Abstract 1595
Background
Recent evidence supported that netrin-1 involves in colorectal carcinogenesis. This study was to evaluate the performance of serum netrin-1 for detection of colorectal cancer (CRC) in both a clinical set and a screening set.
Methods
A total of 115 consecutive patients with CRC and matched healthy controls were included in Clinical Set. Fifty subjects with CRC, 50 subjects with advanced adenoma (AA), and 150 matched control participants free of neoplasia were included in Screening Set. Circulating levels of netrin-1 were evaluated with commercial ELISA kits.
Results
In Clinical set, subjects with CRC presented higher levels of serum netrin-1 (513.9 ± 22.6 pg/mL) than controls (347.8 ± 20.3 pg/mL, p < 0.0001). Similar in Screening set, serum levels of netrin-1 was higher in CRC (644.5 ± 37.0 pg/mL), in comparison with controls (407.7 ± 14.8 pg/mL, p < 0.0001) and AA (416.5 ± 18.5 pg/mL, p < 0.0001). However, there was no difference between controls and AA (p = 0.752). Compared with the low netrin-1 group, the high group presented increased risk of CRC (Clinical set: OR = 4.300 [95% CI 2.473 – 7.477], p < 0.001); Screening set: OR = 7.731 [95% CI 3.618 – 16.519], p < 0.001). ROC curve of netrin-1 was developed to detect CRC (Clinical set: AUC 0.703 [95% CI 0.636 – 0.770]; Screening set: AUC 0.759 [95% CI 0.680 – 0.837]).Table: 147P
Study population characteristics
Clinical set | Screening set | ||||
---|---|---|---|---|---|
Controls | CRC | Controls | AA | CRC | |
Number | 115 | 115 | 150 | 50 | 50 |
Netrin-1 levels (pg/ml) | 347.8 ± 20.3* | 513.9 ± 22.6* | 407.7 ± 14.8# | 416.5 ± 18.5^ | 644.5 ± 37.0#^ |
Age (years) | 53.8 ± 8.7 | 55.9 ± 9.1 | 54.2 ± 9.2 | 51.9 ± 10.0 | 55.8 ± 9.6 |
Sex | |||||
Male | 92 | 92 | 111 | 37 | 37 |
Female | 23 | 23 | 39 | 13 | 13 |
BMI (kg/m2) | 22.8 ± 3.0 | 24.6 ± 3.9 | 22.4 ± 2.9 | 23.1 ± 3.1 | 23.7 ± 3.1 |
WHR | 0.89 ± 0.08 | 0.92 ± 0.06 | 0.88 ± 0.08 | 0.94 ± 0.09 | 0.99 ± 0.07 |
TNM stage | |||||
I | 16 | 10 | |||
II | 43 | 22 | |||
III | 42 | 13 | |||
IV | 14 | 5 | |||
Location | |||||
Colon | 83 | 34 | |||
Rectum | 32 | 16 |
Data are mean ± SD for continuous variables.
*p < 0.001; #p < 0.001; ∧p < 0.001. AA, advanced adenomas; BMI, body mass index; WHR, waist-to-hip circumference ratio.
Conclusions
It suggests netrin-1 as a potential biomarker in the screening and detection of CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Soochow University.
Funding
Jiangsu Provincial Key Research and Development Plan (No. BE2018659) and Provincial Key Laboratory Program of Higher Education (No. KJS1867).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract
1117 - Biomarkers predictive of overall survival in advanced cancer patients treated with a peptide-based cancer vaccine.
Presenter: Shigetaka Suekane
Session: Poster Display session 3
Resources:
Abstract
1922 - Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumor tissues
Presenter: Shaorong Yu
Session: Poster Display session 3
Resources:
Abstract
5495 - Patient’s perspective on digital biomarkers in advanced urologic malignancies
Presenter: Severin Rodler
Session: Poster Display session 3
Resources:
Abstract
3166 - A comprehensive Pan-cancer study of FGFR Aberrations in Chinese cancer patients
Presenter: Yang Gao
Session: Poster Display session 3
Resources:
Abstract
3277 - A Systemic Inflammation Response Index (SIRI) correlates with survival and could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer (PC)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 3
Resources:
Abstract
2680 - Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced Non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel)
Presenter: Alberto Pavan
Session: Poster Display session 3
Resources:
Abstract
4066 - Breast cancer in young women of Kazakh population depending on germline mutations: results of next-generation sequencing
Presenter: Dilyara Kaidarova
Session: Poster Display session 3
Resources:
Abstract
5514 - Discovery of an ImmunoTranscriptomics signature in blood for early colorectal cancer detection
Presenter: Paolo Angelino
Session: Poster Display session 3
Resources:
Abstract
2036 - Salivary metabolomics for colorectal cancer detection
Presenter: Hiroshi Kuwabara
Session: Poster Display session 3
Resources:
Abstract